Nivolumab + Cabozantinib

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Carcinoid Tumor

Conditions

Carcinoid Tumor, Carcinoid Tumor of GI System, Neuroendocrine Tumors

Trial Timeline

Dec 26, 2019 → Jan 31, 2024

NCT ID

NCT04197310

About Nivolumab + Cabozantinib

Nivolumab + Cabozantinib is a phase 2 stage product being developed by Bristol Myers Squibb for Carcinoid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT04197310. Target conditions include Carcinoid Tumor, Carcinoid Tumor of GI System, Neuroendocrine Tumors.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04197310	Phase 2	Completed	Dec 26, 2019	Jan 31, 2024	Carcinoid Tumor
NCT03316586	Phase 2	Completed	Nov 30, 2017	Aug 30, 2019	Breast Cancer

Competing Products

20 competing products in Carcinoid Tumor

See all competitors

Product	Company	Stage	Hype Score
Ramucirumab + Somatostatin Analog	Eli Lilly	Phase 2	52
Pasireotide	Novartis	Phase 1	33
Pasireotide + Octreotide	Novartis	Phase 3	77
Pasireotide (SOM230)	Novartis	Phase 2	52
Octreotide + Placebo + Everolimus	Novartis	Phase 3	77
Lutathera	Novartis	Phase 2	52
EPO906 epothilone B	Novartis	Phase 2	52
Panitumumab	Amgen	Phase 2	51
Axitinib	Pfizer	Phase 2	51
Lanreotide + Placebo (for sunitinib) + Sunitinib	Pfizer	Phase 2	51
bevacizumab + 5-fluorouracil + leucovorin + oxaliplatin	Sanofi	Phase 2/3	64
lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)	Ipsen	Phase 3	74
lanreotide (Autogel formulation)	Ipsen	Approved	82
Lanreotide + Placebo	Ipsen	Phase 3	74
BIM 23A760	Ipsen	Phase 2	49
Randomized: 40 mg Paltusotine + Randomized: 80 mg Paltusotine	Crinetics Pharmaceuticals	Phase 2	47
Paltusotine + Placebo	Crinetics Pharmaceuticals	Phase 3	72
Telotristat etiprate + Placebo-matching telotristat etiprate	Lexicon Pharmaceuticals	Phase 3	72
Telotristat etiprate	Lexicon Pharmaceuticals	Phase 3	72
500 mg [14C]-LX1606	Lexicon Pharmaceuticals	Phase 1	28

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved